Menu

Why invest in GSK?

GSK is a biopharma company focused on preventing and treating disease through specialty medicines, vaccines, and general medicines.

With £32.7bn in total sales in 2025 and more than 50 pipeline assets across four core therapeutic areas — respiratory, immunology and inflammation; oncology; HIV; and infectious diseases — GSK offers investors a combination of near-term commercial momentum and a strengthening late-stage pipeline.

Our strategy

We prevent and treat disease with specialty medicines, vaccines and general medicines. We focus on the science of the immune system and advanced technologies, investing in four core therapeutic areas – respiratory, immunology and inflammation; oncology; HIV; and infectious diseases – to impact health at scale.

We're prioritising three areas to drive value in 2026:

  1. Deliver growth: Maximising the launch of our next wave of products and ensuring overall operational execution success.​

  2. Accelerate R&D: Getting key assets in our late-stage pipeline to patients faster and executing targeted business development.​

  3. Simplify how we work: Driving a step change, including the adoption of AI and technology, to ensure we are competitive and investing our resources effectively.​

We have a strong patient-driven purpose and culture, and a commitment to operating responsibly for all our stakeholders.

We have a clear strategy to develop a high-quality portfolio of specialty medicines and vaccines. The priority now is delivery and overall operational execution.

Luke Miels

Our business model

As a focused biopharma company, we discover, develop and deliver medicines and vaccines to create value for patients and shareholders. We aim to positively impact the health of 2.5 billion people by the end of the decade.

A scientist smiling and making a heart shape with their hands in purple gloves, a green gown and protective head gear

Central to our success are our people: experts in science, technology, manufacturing and commercialisation.

66,800
GSK people across 70 countries worldwide*

£7.5bn
R&D investment*

33
Manufacturing sites*

18,000
Suppliers working directly with GSK*

*as at 31 December 2025

Financial highlights

In 2025, we delivered another year of strong performance with growth in sales, core operating profit and earnings driven by Specialty Medicines.

GSK Tech Human Image
Financial performance
Download our 2025 KPIs

  • £32.7bn

    Total sales (up 7% CER)

  • £13.5bn

    Specialty Medicines (up 17% CER)

  • £9.2bn

    Vaccines (up 2% CER)

  • £10.0bn

    General Medicines (down 1% CER)

R&D performance

In 2025, we continued to strengthen our late-stage pipeline with organic R&D delivery and targeted business development, supporting future growth.

  • £8bn

    Innovation sales of products launched, or with major lifecycle innovation expansion, in the last five years*

  • 5

    Major US Food and Drug Administration (FDA) approvals in 2025*

  • 17

    Assets in phase III/registration*

  • 7

    Pivotal trial starts*

  • 58

    Assets in the pipeline*

  • 14

    New partnerships and acquisitions*

*as at 31 December 2025

5 key approvals in 2025

Lungs Science Image

Severe asthma

Exdensur

Respiratory diseases such as severe asthma pose significant challenges to millions of patients worldwide. In 2025, Exdensur was approved in the US for the treatment of severe asthma with an eosinophilic phenotype. Its ultra-long-acting profile and twice-yearly dosing offers patients sustained protection from exacerbations and could help reduce hospital stays and limit cumulative lung damage. It is also approved for patients with chronic rhinosinusitis with nasal polyps (CRSwNP) in several other markets.

Science Image Multiple Myeloma RGB

Multiple myeloma

Blenrep

Multiple myeloma is a complex blood cancer that is generally considered treatable but not curable, with nearly all patients experiencing relapse as the disease becomes resistant to available treatments. Blenrep, in combination, was approved by the US FDA in October 2025 after two or more lines of therapy, and in other markets, following one or more prior treatment lines. As the only anti-BCMA antibody drug conjugate (ADC) that is accessible across healthcare settings, including in community centres where 70% of patients receive care, Blenrep could fulfil a major patient need.

Eosinophils science image

COPD

Nucala

Many chronic obstructive pulmonary disease (COPD) patients experience persistent symptoms and exacerbations – acute episodes of worsening symptoms – which can result in hospitalisation and irreversible lung damage. In May, Nucala was approved by the US FDA for use in adults with COPD characterised by an eosinophilic phenotype, providing an important option for COPD patients. The approval was based on data which included a reduction of exacerbations leading to hospitalisation and/or emergency department visits.

Escherichia Coli (E. Coli) Bacteria Science Image

uUTI and uncomplicated gonorrhoea

Blujepa

More than half of all women experience an uncomplicated urinary tract infection (uUTI) in their lifetime. In 2025, Blujepa was approved in the US as an oral treatment for uUTI. It was also approved in the US for uncomplicated gonorrhoea which affects both men and women, and can lead to infertility and other reproductive health complications. Blujepa is the first in a new class of oral antibiotics for these conditions in nearly 30 years.

Invasive meningococcal disease science image

Invasive meningococcal disease

Penmenvy

Invasive meningococcal disease (IMD) is a rare but devastating illness that can progress rapidly and lead to death or long-term, life-changing consequences. Penmenvy, our new 5-in-1 vaccine for IMD, was approved in the US in 2025 and is now part of the adolescent meningococcal immunisation schedule. By reducing the number of injections needed for protection, Penmenvy could increase immunisation rates and help protect more young people from this serious disease.

You might also like

Quarterly results

Discover our latest financial performance announcement and search for historical quarterly results materials

GSK at a glance

We prioritise innovation in specialty medicines and vaccines to prevent and treat disease.

Pipeline

Our pipeline is focused on unlocking the science of the immune system and advanced technologies to develop innovative medicines and vaccines

Continue to Quarterly results